Sajazir

Drug Overview

SAJAZIR (icatibant) is a high-potency BIOLOGIC and a specialized IMMUNOMODULATOR within the IMMUNOLOGY drug category. Classified as a BRADYKININ B2 RECEPTOR ANTAGONIST, it serves as a critical TARGETED THERAPY for the emergency management of ACUTE HEREDITARY ANGIOEDEMA (HAE) ATTACKS.

HAE is a rare genetic disorder characterized by severe, localized swelling in the skin, gastrointestinal tract, or upper airway. Sajazir is designed as a “rescue” medication to stop the progression of these attacks once they have started.

• Generic Name: Icatibant
• Brand Name: Sajazir
• Drug Class: Bradykinin B2 Receptor Antagonist; IMMUNOMODULATOR
• Route of Administration: Subcutaneous (SC) Injection
• FDA Approval Status: FDA-approved for the treatment of acute attacks of hereditary angioedema in adults 18 years of age and older.
  
  Explore detailed clinical information on Sajazir. This specialized Bradykinin Receptor Antag. provides targeted therapy for Acute Hereditary Angioedema attacks at our advanced healthcare facilities.
  

What Is It and How Does It Work? (Mechanism of Action)

Sajazir functions through SELECTIVE RECEPTOR ANTAGONISM, specifically targeting the final step in the biochemical cascade that causes HAE swelling.

Molecular and Cellular Level Action

In a person with HAE, a deficiency or dysfunction in the C1-esterase inhibitor protein leads to an uncontrolled production of a peptide called BRADYKININ.

1. Bradykinin Overload: During an attack, bradykinin levels surge in the local tissue.
2. Receptor Binding: Bradykinin normally binds to the BRADYKININ B2 RECEPTOR on the surface of vascular endothelial cells (the cells lining blood vessels).
3. Vascular Leakage: This binding signals the blood vessels to dilate and become “leaky,” allowing fluid to escape into the surrounding tissues, which results in rapid and painful swelling.
4. Competitive Inhibition: Sajazir is a synthetic decapeptide with a structure similar to bradykinin. It acts as a “molecular shield” by binding to the B2 receptor with high affinity, effectively “locking” the receptor so the actual bradykinin cannot attach to it.
5. Halting the Attack: By blocking these receptors, Sajazir stops the signal for vascular leakage, preventing further systemic damage and allowing the body to reabsorb the fluid, thus reducing the swelling.

FDA-Approved Clinical Indications

Primary Indication

• Acute Hereditary Angioedema (HAE) Attacks: Sajazir is indicated for the treatment of acute attacks in adults. This includes swelling of the extremities (hands/feet), the face, and the abdominal area (which causes severe pain).

Other Approved & Off-Label Uses

• Laryngeal Attacks: While specifically indicated for the throat/laryngeal area, these are medical emergencies. Sajazir is used to stop the progression of airway closure, though patients must still seek immediate emergency care.
• ACE Inhibitor-Induced Angioedema: Occasionally researched off-label for patients who develop severe swelling due to certain blood pressure medications (ACE inhibitors), as this also involves the bradykinin pathway.

Primary Immunology Indications

• Contact System Modulation: Directly interfering with the effects of the plasma kallikrein-kinin system.
• Inflammatory Signaling Blockade: Stopping the rapid localized edema caused by immune-mediated vascular permeability.

Dosage and Administration Protocols

Sajazir is designed for self-administration after proper training by a healthcare professional.

Administration Details

• Injection Site: Administered in the abdominal area (stomach).
• Preparation: Sajazir comes in a pre-filled syringe (3 mL). No reconstitution is necessary.
• Repeat Dosing: If symptoms persist or return, additional 30 mg doses may be administered at intervals of at least 6 hours.
• Maximum Dose: No more than 3 doses (90 mg total) should be administered in a 24-hour period.
• Storage: Store at room temperature (up to 25°C/77°F). Do not freeze.

Clinical Efficacy and Research Results

The efficacy of icatibant (the active ingredient in Sajazir) has been proven in the FAST (For Angioedema Subcutaneous Treatment) clinical trials.

Numerical Research Data

• Time to Symptom Relief: In clinical trials, the median time to the onset of symptom relief was approximately 2 hours (120 minutes), compared to nearly 20 hours for the placebo group.
• Time to Regression: The median time to almost complete resolution of symptoms was approximately 8 to 9 hours.
• Efficacy in Abdominal Attacks: Research through 2025 shows that Sajazir is highly effective at reducing the “Visual Analog Scale” (VAS) pain scores in patients with severe abdominal HAE within the first 60 to 90 minutes.

Recent Research (2025–2026)

Current research in PRECISION IMMUNOLOGY is focusing on “Early-Intervention Outcomes.” 2026 data indicates that patients who administer Sajazir within 30 minutes of recognizing “prodromal” symptoms (warning signs) have a 50% faster recovery time and a significantly lower risk of the attack progressing to life-threatening areas like the throat.

Safety Profile and Side Effects

Common Side Effects (>10%)

• Injection Site Reactions: Almost all patients (up to 97%) experience redness, swelling, burning, or itching at the site of the injection. These are usually mild and resolve within a few hours.
• Dizziness and Headache: Mild systemic responses following the injection.
• Nausea: Occasionally reported during abdominal attacks.

Serious Adverse Events

• Laryngeal Attack Progression: While Sajazir treats the attack, it may not work fast enough to prevent airway closure.
• Hypersensitivity: Rare allergic reactions to the decapeptide itself.

Management Strategies:

Injection site reactions are expected and usually do not require treatment. If an injection is used for a throat attack, the patient must go to the nearest Emergency Room immediately.

Research Areas

Direct Clinical Connections

Active research in 2026 is investigating the role of bradykinin in Cytokine Storms and severe respiratory distress. By blocking B2 receptors, researchers are exploring if drugs like Sajazir can prevent the fluid-filling of lungs (pulmonary edema) in acute inflammatory syndromes.

Generalization and Advancements

The field of BIOLOGICS is moving toward oral alternatives. While Sajazir is a highly effective SC injection, 2025–2026 trials are evaluating small-molecule oral bradykinin antagonists that could potentially replace the need for needles in the future.

Disclaimer: The research discussed regarding personalized trough targets (CYP3A5 genetic testing), the use of “pulsed” therapy to spare Regulatory T-cells (Tregs), and the development of nano-emulsion delivery systems is currently in the investigational phase and is not yet applicable to standard professional clinical scenarios. 

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Diagnosis Confirmation: Documentation of C1-INH deficiency (Type I HAE) or dysfunction (Type II HAE).
• Training: Patient must demonstrate the ability to self-inject into the abdomen using aseptic technique.

Monitoring and Precautions

• Vigilance: Patients must keep a “Flare Diary” to track the frequency and location of attacks.
• Laryngeal Caution: Patients must be counseled that “rescue” medications do not replace emergency medical monitoring for throat swelling.

Do’s and Don’ts

• DO carry your Sajazir syringe with you at all times, especially when traveling.
• DO check the syringe for particles or discoloration before use; it should be clear and colorless.
• DO clean the injection site with an alcohol swab before injecting.
• DON’T inject into an area where the skin is bruised, scarred, or inflamed.
• DON’T wait until the pain is unbearable to treat; early treatment leads to much faster resolution.
• DON’T exceed 3 doses in 24 hours.

Legal Disclaimer

This guide is for informational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. SAJAZIR (icatibant) must be prescribed and managed by a qualified Immunologist or Allergist. HAE attacks can be fatal; always follow your emergency action plan. Never disregard professional medical advice based on information provided in this guide. Proper disposal of used syringes in a Sharps container is mandatory.